ID NOW COVID-19即时检测与实验室核酸检测的一致性比较
该研究比较了在非传统实验室场景下使用的ID NOW COVID-19即时核酸检测与实验室核酸检测的一致性。通过分析9,518对配对检测结果,发现两种方法具有强一致性(κ=0.88,OPA=98.3%),表明在全面质量管理体系下ID NOW可用于非传统实验室环境的SARS-CoV-2检测。
要点
- ID NOW与实验室NAAT配对检测9,518对,总符合率98.3%,κ=0.88。
- 非传统实验室使用ID NOW需配套安全评估、培训与质控监测。
- 在全面质量管理体系下,ID NOW可用于即时SARS-CoV-2检测。
核心结论
- 在全面质量管理体系下,ID NOW COVID-19检测可在非传统实验室场景用于SARS-CoV-2检测。
研究设计与样本
- 比较ID NOW COVID-19即时核酸检测与实验室核酸检测的配对检测研究,共纳入9,518对检测结果。
- DC DFS PHL在移动检测单元、健康诊所和急诊科等非传统实验室场景实施ID NOW检测,并提供安全风险评估、检测培训、能力评估和质控监测。
主要发现
- ID NOW COVID-19检测与实验室NAAT之间呈强一致性,κ=0.88,总符合率(OPA)为98.3%。
关键数值与推荐
- 配对检测9,518对,κ=0.88,OPA=98.3%。
临床怎么用
- 在非传统实验室场景使用ID NOW COVID-19检测时,应配套安全风险评估、检测培训、能力评估和质控监测等全面质量管理措施。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The emergence of a novel coronavirus, namely, SARS-CoV-2, necessitated the use of rapid, accurate diagnostics to quickly diagnose COVID-19. This need has increased with the emergence of new variants and continued waves of COVID-19 cases. The ID NOW COVID-19 assay is a rapid nucleic acid amplification test (NAAT) that is used by hospitals, urgent care facilities, medical clinics, and public health laboratories for rapid molecular SARS-CoV-2 testing at the point of care. The District of Columbia Department of Forensic Sciences Public Health Laboratory Division (DC DFS PHL) implemented ID NOW COVID-19 testing in nontraditional laboratory settings, including a mobile testing unit, health clinic, and emergency department, to assist with rapid identification and isolation for populations at high risk of SARS-CoV-2 transmission in the District of Columbia. The DC DFS PHL provided these nontraditional laboratories with safety risk assessment, assay training, competency assessment, and quality control monitoring as parts of a comprehensive quality management system (QMS). We assessed the accuracy of the ID NOW COVID-19 assay when operated in the context of these trainings and systems. This was done by comparing results from 9,518 paired tests, and strong agreement (κ = 0.88, OPA = 98.3%) was found between the ID NOW COVID-19 assay and laboratory-based NAATs. These findings indicate that the ID NOW COVID-19 assay can be used to detect SARS-CoV-2 in nontraditional laboratory settings when used within the context of a comprehensive QMS.
引用
- Payne D, Williams C, Jacob J, et al. Comparison of an ID NOW COVID-19 Assay Used at the Point of Care to Laboratory-Based Nucleic Acid Amplification Tests. J Clin Microbiol. 2023. PMID: 37395672. doi:10.1128/jcm.00413-23
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。